Literature DB >> 24562640

Altered serotonin transporter availability in patients with multiple sclerosis.

Swen Hesse1, Franziska Moeller, David Petroff, Donald Lobsien, Julia Luthardt, Ralf Regenthal, Georg-Alexander Becker, Marianne Patt, Eva Thomae, Anita Seese, Philipp M Meyer, Florian Then Bergh, Osama Sabri.   

Abstract

PURPOSE: Modulation of the immune system by the CNS may involve serotonergic regulation via the brain serotonin transporters (SERT). This regulation may be disturbed in patients with CNS disorders including multiple sclerosis (MS). Central serotonergic mechanisms have not been investigated in MS by in vivo imaging. The objective of the study was to assess the availability of SERT in antidepressant-naive patients with MS by means of PET.
METHODS: Included in this study were 23 patients with MS and 22 matched healthy volunteers who were investigated with PET and the SERT-selective marker [(11)C]DASB, and distribution volume ratios were determined. Clinical assessment of the patients included the expanded disability status scale, the MS fatigue scale Würzburger Erschöpfungsinventar bei MS (WEIMuS) and the Beck Depression Inventory (BDI). The PET data were analysed with both volume-of-interest and voxel-based analyses to determine regional SERT availability.
RESULTS: Patients had lower SERT availability in the cingulate cortex, the thalamus and the insula, and increased availability in the orbitofrontal cortex. Patients with relapsing/remitting MS tended to have lower SERT in the hippocampus, whereas patients with primary progressive disease showed increased SERT availability in prefrontal regions. There was a positive correlation between SERT availability in the insula and both depression and fatigue scores (r = 0.56 vs. BDI, p = 0.02; r = 0.49 vs. WEIMuS, p = 0.05).
CONCLUSION: Serotonergic neurotransmission in MS patients is altered in limbic and paralimbic regions as well as in the frontal cortex that this appears to contribute to psychiatric symptoms of MS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24562640     DOI: 10.1007/s00259-013-2636-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  30 in total

1.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

Review 2.  Immunopathogenesis and immunotherapy of multiple sclerosis.

Authors:  Bernhard Hemmer; Stefan Nessler; Dun Zhou; Bernd Kieseier; Hans-Peter Hartung
Journal:  Nat Clin Pract Neurol       Date:  2006-04

Review 3.  Multiple sclerosis-associated fatigue.

Authors:  Lauren B Krupp; Dana J Serafin; Christopher Christodoulou
Journal:  Expert Rev Neurother       Date:  2010-09       Impact factor: 4.618

4.  Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.

Authors:  Nicola Pavese; Vinod Metta; Subrata K Bose; Kallol Ray Chaudhuri; David J Brooks
Journal:  Brain       Date:  2010-09-30       Impact factor: 13.501

5.  Reduction of serotonin transporters of patients with chronic fatigue syndrome.

Authors:  Shigeyuki Yamamoto; Yasuomi Ouchi; Hirotaka Onoe; Etsuji Yoshikawa; Hideo Tsukada; Hidetoshi Takahashi; Masao Iwase; Kouzi Yamaguti; Hirohiko Kuratsune; Yasuyoshi Watanabe
Journal:  Neuroreport       Date:  2004-12-03       Impact factor: 1.837

Review 6.  Emotional valence modulates brain functional abnormalities in depression: evidence from a meta-analysis of fMRI studies.

Authors:  Nynke A Groenewold; Esther M Opmeer; Peter de Jonge; André Aleman; Sergi G Costafreda
Journal:  Neurosci Biobehav Rev       Date:  2012-12-01       Impact factor: 8.989

7.  Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI.

Authors:  Yaou Liu; Yunyun Duan; Peipeng Liang; Xiuqin Jia; Chunshui Yu; Jing Ye; Helmut Butzkueven; Huiqing Dong; Kuncheng Li
Journal:  Acta Radiol       Date:  2012-09-21       Impact factor: 1.990

8.  The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy.

Authors:  Ashley Martinez; Andrey Finegersh; Dara M Cannon; Irene Dustin; Alison Nugent; Peter Herscovitch; William H Theodore
Journal:  Neurology       Date:  2013-03-20       Impact factor: 9.910

9.  Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.

Authors:  Claudio Solaro; Roberto Bergamaschi; Cristiana Rezzani; Margit Mueller; Erika Trabucco; Valeria Bargiggia; Francesca Dematteis; Alessandra Mattioda; Vincenzo Cimino; Domenico Restivo; Francesco Patti; Paola Cavalla
Journal:  Clin Neuropharmacol       Date:  2013 Jul-Aug       Impact factor: 1.592

10.  Relating brain damage to brain plasticity in patients with multiple sclerosis.

Authors:  Valentina Tomassini; Heidi Johansen-Berg; Saad Jbabdi; Richard G Wise; Carlo Pozzilli; Jacqueline Palace; Paul M Matthews
Journal:  Neurorehabil Neural Repair       Date:  2012-02-09       Impact factor: 3.919

View more
  21 in total

Review 1.  Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2018-02-10       Impact factor: 3.843

2.  Major depression favors the expansion of Th17-like cells and decrease the proportion of CD39+Treg cell subsets in response to myelin antigen in multiple sclerosis patients.

Authors:  Priscila Mendonça do Sacramento; Marisa Sales; Taissa de Matos Kasahara; Clarice Monteiro; Hugo Oyamada; Aleida Soraia Oliveira Dias; Lana Lopes; Camilla Teixeira Castro; Átila Duque Rossi; Lucas Mattos Milioni; Anshu Agrawal; Regina Alvarenga; Claudia Cristina Vasconcelos; Cleonice Alves de Melo Bento
Journal:  Cell Mol Life Sci       Date:  2022-05-18       Impact factor: 9.261

Review 3.  The Link Between Energy-Related Sensations and Metabolism: Implications for Treating Fatigue.

Authors:  Marco Filippi; Rainer Krähenmann; Patrick Fissler
Journal:  Front Psychol       Date:  2022-06-21

Review 4.  Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.

Authors:  Aline M Thomas; Frederik Barkhof; Jeff W M Bulte
Journal:  Radiology       Date:  2022-04-26       Impact factor: 29.146

Review 5.  The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders.

Authors:  Ekaterina Dobryakova; Helen M Genova; John DeLuca; Glenn R Wylie
Journal:  Front Neurol       Date:  2015-03-12       Impact factor: 4.003

Review 6.  The representation of inflammatory signals in the brain - a model for subjective fatigue in multiple sclerosis.

Authors:  Katrin Hanken; Paul Eling; Helmut Hildebrandt
Journal:  Front Neurol       Date:  2014-12-11       Impact factor: 4.003

7.  Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2+ and TLR4+ Th17/Tc17-like cells in multiple sclerosis patients with major depression.

Authors:  Marisa C Sales; Taissa M Kasahara; Priscila M Sacramento; Átila D Rossi; Marcos Octávio S D Cafasso; Hugo A A Oyamada; Joana Hygino; Fabianna Alvim; Regis M Andrade; Cláudia Cristina Vasconcelos; Cleonice A M Bento
Journal:  Immunology       Date:  2020-11-23       Impact factor: 7.397

Review 8.  Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation.

Authors:  Moussa A Chalah; Naji Riachi; Rechdi Ahdab; Alain Créange; Jean-Pascal Lefaucheur; Samar S Ayache
Journal:  Front Cell Neurosci       Date:  2015-11-30       Impact factor: 5.505

9.  Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications.

Authors:  Antonio Carotenuto; Heather Wilson; Beniamino Giordano; Silvia P Caminiti; Zachary Chappell; Steven C R Williams; Alexander Hammers; Eli Silber; Peter Brex; Marios Politis
Journal:  J Neurol       Date:  2020-03-26       Impact factor: 4.849

Review 10.  Serotonin: A mediator of the gut-brain axis in multiple sclerosis.

Authors:  Tsveta S Malinova; Christine D Dijkstra; Helga E de Vries
Journal:  Mult Scler       Date:  2017-11-09       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.